Learning Optimal Personalized Treatment Rules in Consideration of Benefit and Risk: With an Application to Treating Type 2 Diabetes Patients With Insulin Therapies
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Individualized medical decision making is often complex due to patient treatment response heterogeneity. Pharmacotherapy may exhibit distinct efficacy and safety profiles for different patient populations. An "optimal" treatment that maximizes clinical benefit for a patient may also lead to concern of safety due to a high risk of adverse events. Thus, to guide individualized clinical decision making and deliver optimal tailored treatments, maximizing clinical benefit should be considered in the context of controlling for potential risk. In this work, we propose two approaches to identify personalized optimal treatment strategy that maximizes clinical benefit under a constraint on the average risk. We derive the theoretical optimal treatment rule under the risk constraint and draw an analogy to the Neyman-Pearson lemma to prove the theorem. We present algorithms that can be easily implemented by any off-the-shelf quadratic programming package. We conduct extensive simulation studies to show satisfactory risk control when maximizing the clinical benefit. Lastly, we apply our method to a randomized trial of type 2 diabetes patients to guide optimal utilization of the first line insulin treatments based on individual patient characteristics while controlling for the rate of hypoglycemia events. We identify baseline glycated hemoglobin level, body mass index, and fasting blood glucose as three key factors among 18 biomarkers to differentiate treatment assignments, and demonstrate a successful control of the risk of hypoglycemia in both the training and testing data set.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919 · cited 5×
“This observation reflects the fact that patientswith a lowblood glucose level are at a higher risk of experiencing hypoglycemia events, which is consistent with the diabetes treatment guidance (American Diabetes Association and others 2014).”
BackgroundInfluentialCryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160 · cited 4×
“In addition, fear of hypoglycemia can lead to medication noncompliance and failure to achieve glycemic control (Cryer et al., 2003).”
BackgroundInfluentialHypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
Cryer, P. (2002) · Diabetologia · doi:10.1007/s00125-002-0822-9 · Cited by 794 · cited 2×
“While the progressive nature of the disease requires an escalating sequence of medications or dose of insulin, the risk of hypoglycemia and other adverse events may increase with the intensified treatment (Cryer, 2002).”
Background
Cited by
Kwon, Y., Won, J.-H., Kim, B. J., & Paik, M. C. (2020) · Computational Statistics & Data Analysis · doi:10.1016/j.csda.2019.106816 · Cited by 424
Kosorok, M. R., & Laber, E. B. (2019) · Annual Review of Statistics and Its Application · doi:10.1146/annurev-statistics-030718-105251 · Cited by 370
Reinforcement learning for intelligent healthcare applications: A survey
Coronato, A., Naeem, M., De Pietro, G., & Paragliola, G. (2020) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2020.101964 · Cited by 320
Artificial intelligence in diabetes management: Advancements, opportunities, and challenges
Guan, Z., Li, H., Liu, R., Cai, C., Liu, Y., Li, J., Wang, X., Huang, S., Wu, L., Liu, D., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101213 · Cited by 412
“83 For both T1D and T2D, Nguyen et al. leveraged tree-based methods to predict whether patients would require more than 6 units of total daily dosing, which achieved an AUROC of 0.85.”
BackgroundInfluentialA Gentle Introduction to Reinforcement Learning and its Application in Different Fields
Naeem, M., Rizvi, S. T. H., & Coronato, A. (2020) · IEEE Access · doi:10.1109/access.2020.3038605 · Cited by 257
Metadata
- Authors
- Wang, Y., Fu, H., & Zeng, D.
- Venue
- Journal of the American Statistical Association
- Publisher
- Informa UK Limited
- Published
- 2018-01-02
- Volume
- 113
- Issue
- 521
- Pages
- 1-13
- ISSN
- 0162-1459 (ISSN-L)
- 1537-274X
- OpenAlex
- W2599189192
- Cited by
- 78
- References
- 4
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Learning Optimal Personalized Treatment Rules in Consideration of Benefit and Risk: With an Application to Treating Type 2 Diabetes Patients With Insulin Therapies. https://app.cochat.ai/papers/10.1080/01621459.2017.1303386
- The paper
- Wang, Y., Fu, H., & Zeng, D. (2018). Learning Optimal Personalized Treatment Rules in Consideration of Benefit and Risk: With an Application to Treating Type 2 Diabetes Patients With Insulin Therapies. Journal of the American Statistical Association. https://doi.org/10.1080/01621459.2017.1303386
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.